Biogen, Inc. (NASDAQ/BGEN) announced today that Nicolas Barthelemy has been appointed Vice President, Manufacturing and General Manager of the Company’s Research Triangle Park (RTP), North Carolina facility. Mr. Barthelemy will supervise Biogen’s RTP operations, which is now home to the large-scale manufacturing plant (LSM), one of the largest cell culture facilities in the world, and more than 300 employees. He will also oversee the Cambridge manufacturing site and its 150 employees. He reports to Sylvie Gregoire, Pharm.D., Executive Vice President, Technical Operations.

Dr. Gregoire said, “Nicolas has played a critical role in making RTP a world-class manufacturing facility. The addition of the LSM gives Biogen one of the largest biologic manufacturing capacities in the world, and the flexibility to produce multiple products in our growing pipeline. Nicolas’ leadership as general manager and diverse experience will be critical for Biogen to maintain a first-rate manufacturing capability and for RTP to become a multifunctional operation.”

Mr. Barthelemy was most recently Director of Manufacturing in RTP, where he oversaw 140 people in the manufacturing, validation, materials management and technical services groups during a period of rapid growth and the start-up of the LSM. He joined Biogen in 1996 as Manager, European Supply Chain. From 1998 to 2000 he was Regional Manager, Distributors and then Associate Director, International Distributors, supervising the sales, marketing and product launch responsibilities of AVONEX® (Interferon beta-1a) in over 30 international markets. Mr. Barthelemy subsequently served as a member of the senior management team responsible for establishing Biogen’s presence in Asia. Prior to joining Biogen, he was at Merck & Co., Inc., where he worked in Technical Operations.

Mr. Barthelemy received a Master of Science in Physics and Chemistry from Ecole Superieure de Physiques et Chimie Industrielles in Paris, France. He also received a Master of Science in Chemical Engineering at University of California at Berkeley and attended the Harvard Business School Program for Management Development.

About Biogen

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biotechnology
company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, (Please see full prescribing information at, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s homepage on the World Wide Web at